Prostate cancer Cancer Prostate
Conditions
Interventions
1. Group A: Castration, medical or surgical
2. Group B: Casodex (bicalutamide) taken orally. Cohorts of patients were recruited sequentially, into each arm of the randomised stages, to
Sponsors
AstraZeneca Clinical Research Group (UK)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Histologically/cytologically confirmed metastatic or locally advanced (T3 or T4) prostate carcinoma. Confirmed within the last month 2. Life expectancy of more than 3 months 3. Prostate specific antigen (PSA) of at least five-times upper limit of normal reference range 4. Evaluable disease and fit to receive any of the treatment options 5. No previous or concurrent systemic therapy for prostate cancer 6. No radiotherapy to the prostate within the 3 months prior to entry into the trial 7. No previous medical history of another malignancy within the past 5 years 8. Adequate cardiac, renal and hepatic function 9. Eastern Cooperative Oncology Group (ECOG) performance 3 or 4
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed